Abstract
e21022
Background: Breast cancer is the most common cancer type in women worldwide. Its early detection is a crucial step for the successful treatment. Although many serum biomarkers were described for breast cancer, all of them still lack of clinical specificity and sensitivity for the early detection. Therefore, we developed and evaluated a proteomics-approach for detection of biomarkers in serum of breast cancer patients and tried to identify differently regulated proteins.
Methods: Blood samples of 50 women with breast cancer (CA) and 50 age-matched healthy women (CTRL) were drawn prior to surgery and respective sera were obtained. We used surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF-MS) for protein profiling with three active surfaces of the protein chips with different binding properties. Data was analyzed by multivariate statistical techniques and artificial neural networks.
Results: We obtained a protein profile with 15 differently regulated proteins. Ten of them were upregulated in sera of breast cancer patients. The diagnostic pattern could discriminate CA from CRTL with specificity of 77% and sensitivity of 85%, the area under curve (AUC) of 0.85 was achieved. Two of upregulated proteins in breast cancer sera are Inter-a (globulin) inhibitor H4 (ITIH4) and Apolipoprotein C-I (ApoC-1).
Conclusions: SELDI-TOF-MS is a promising, non-invasive tool for detection of breast cancer biomarkers with low sample amounts and high sensitivity and specificity. The next step of this project is the identification of all obtained biomarkers from our protein profiles and a validation serum study in a larger study population. The knowledge of different regulated proteins can help to understand the development of cancer, possibly leading to its early detection.
Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 28, No 15_suppl (May 20 Supplement), 2010: e21022
K. Keller, D. Boehm, A. Lebrecht, M. Schmidt, J. Pieter, H. Koelbl and F. Grus
Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz, Germany; Department of Experimental Ophthalmology, Johannes Gutenberg University, Mainz, Germany
Wednesday, September 15, 2010
Lifetime care for patients with autism
Anton R. Miller
University of British Columbia, Division of Developmental Pediatrics, BC Children’s Hospital, Vancouver, BC
The model of care in Nova Scotia proposed by Casey 1 is spot on, but the scope of the project is faulty.
The unrelenting pressure for resources for autism services and research tends to bury at least two important facts. First, many children are challenged by complex neurodevelopmental disorders, and all would benefit from a properly coordinated and accessible system of intervention and support services. It would be unconscionable if discrepancies existed among children with different kinds of cancer — full support for those with bone cancer but meagre support for those with kidney cancer.
Second, it is true that autism and related disorders are diagnosed in more and more children, but the spectrum is broad. The needs of some children and families are complex, but others have fewer needs. Allocation of resources based on a medical diagnosis ignores this crucial fact.
Many professionals involved in the support of children with neurodevelopmental disorders are advocating for child and family support based on need rather than diagnosis. What we really need are regional total care centres for children with complex neurodevelopmental disorders — all those with complex learning and behavioural problems that elude a simple diagnosis.
University of British Columbia, Division of Developmental Pediatrics, BC Children’s Hospital, Vancouver, BC
The model of care in Nova Scotia proposed by Casey 1 is spot on, but the scope of the project is faulty.
The unrelenting pressure for resources for autism services and research tends to bury at least two important facts. First, many children are challenged by complex neurodevelopmental disorders, and all would benefit from a properly coordinated and accessible system of intervention and support services. It would be unconscionable if discrepancies existed among children with different kinds of cancer — full support for those with bone cancer but meagre support for those with kidney cancer.
Second, it is true that autism and related disorders are diagnosed in more and more children, but the spectrum is broad. The needs of some children and families are complex, but others have fewer needs. Allocation of resources based on a medical diagnosis ignores this crucial fact.
Many professionals involved in the support of children with neurodevelopmental disorders are advocating for child and family support based on need rather than diagnosis. What we really need are regional total care centres for children with complex neurodevelopmental disorders — all those with complex learning and behavioural problems that elude a simple diagnosis.
Subscribe to:
Posts (Atom)